2月24日，公考"三巨头"之一粉笔发布业绩预告，预计公司2025年营收、净利润双双下滑。 公告显示，预期公司截至2025年12月31日止年度将录得不少于26.56亿元的收入，相较截至2024年12月31日止年度27.9亿元的收入减少不多于4.8%，主要 是由于中国招录类考试培训行业的竞争持续加剧而导致培训服务的销量及图书的销量下跌；预计将录得不少于1.85亿元的净利润，相较截至2024年12月31 日止年度2.4亿元的净利润减少不多于22.8%。 此外，截至2025年12月31日止年度，经调整净利润预期将不少于2.7亿元，相较截至2024年12月31日止年度的经调整净利润3.63亿元减少不多于25.5%，主 要是由于收入减少。 这是粉笔在2024年营收下滑的基础上业绩再次下滑。 2025年12月14日晚间，粉笔发布公告表示，2025年12月12日，该公司与华图山鼎（300492）订立战略合作协议，双方建立战略合作关系，发挥各自资源互 补优势，提升双方整体竞争力。2025年12月15日，华图也宣布了双方合作的消息。 此次粉笔与华图合作，有声音认为，标志着公考教育行业迎来里程碑式转折阶段，将从根本上改变由粉笔、华 ...

Core Viewpoint - Jingtai Technology has successfully delivered an automated workstation for formula stability testing to BASF, marking a significant advancement in chemical automation and validating its technical and commercial capabilities [1][2]. Group 1: Company Achievements - Jingtai Technology's automated laboratory solutions have been instrumental in various fields, including drug development, petrochemicals, new energy, and new materials, providing high-precision research data [2]. - The successful implementation of the collaboration with BASF is attributed to Jingtai's unique modular standard platform and agile customization capabilities, which have been successfully delivered in high-value areas such as new drug development and chemical synthesis [2][3]. - The automated laboratory not only standardizes experimental operations but also generates high-quality structured data, which is essential for developing proprietary AI models in research and development [3]. Group 2: Market Position and Expansion - Jingtai Technology has established a competitive edge in the field of chemical automation, having served major enterprises and top research institutions, including international pharmaceutical companies and Sinopec [3]. - The business model of "standardized platform + agile customization" allows Jingtai to expand its market boundaries from pharmaceutical research to large-scale chemical and new energy sectors, tapping into trillion-level markets [3]. - BASF, as a global leader in the chemical industry, employs approximately 112,000 people and is projected to achieve global sales of €65.3 billion in 2024, highlighting the scale and significance of the partnership with Jingtai Technology [3].

经济观察网 高新兴（300098）在近7天内披露了多项重要动态。2026年2月6日，公司公告拟募资3.73亿 元，用于提升车载通信产品产能和AI研发能力。同日，公司在互动平台澄清全资子公司高新兴物联无 上市计划。2026年2月9日，公司确认其T-BOX产品具备欧盟NG eCall认证，可通过国内车企合作伙伴出 海，客户包括吉利、长安等主流厂商。2026年2月11日，公司发布2025年业绩预告，预计归母净利润亏 损1800万元至3600万元，同比减亏84.80%至92.40%，并召开临时股东大会。 以上内容基于公开资料整理，不构成投资建议。 近7天高新兴股价呈现震荡走势。2026年2月6日收盘价6.05元，单日下跌1.47%，主力资金净流出 3083.72万元。随后股价小幅波动，截至2026年2月12日最新价为6.18元，近5日涨跌幅为0.65%，但20日 跌幅达13.57%。技术面显示股价处于布林带中轨下方，MACD指标偏弱，短期压力位约7.4元。 财报分析 公司2025年业绩预告显示，营收预计19亿至21亿元，同比增长34%至48%，但连续第四年亏损。亏损收 窄主要源于车载终端业务增长及成本管控优化。前三季 ...

近日，丽珠集团发布投资者调研记录，围绕公司在免疫领域的创新药莱康奇塔单抗及疫苗领域的研发进展进行了详细 交流。 在疫苗领域，公司正在推进流感灭活疫苗和重组人促卵泡激素注射液的研发。四价重组蛋白流感疫苗预计在2026年上 半年进入II期临床，而重组人促卵泡激素注射液预计在2026年内获批上市。公司强调将继续利用AI技术提升研发效 率，缩短研发周期，进一步增强市场竞争力。 公告中提到，在免疫领域，莱康奇塔单抗作为公司的核心标志性成果，目前正在进行中重度银屑病及强直性脊柱炎的 临床研究。其中银屑病适应症已申报上市并纳入CDE优先审评，预计最快在今年底获批。强直性脊柱炎适应症预计在 2026年二季度申报上市。III期临床研究显示，莱康奇塔单抗组第12周PASI100应答率为49.5%，显著优于司库奇尤单抗 的40.2%。此外，公司还启动了海外合作洽谈，未来将探讨新适应症开发。 （丽珠集团公告） ...

Group 1 - The core achievement of the company is the successful delivery of an automated workstation for formulation stability testing to BASF, a global leader in the chemical industry, enhancing BASF's automated system for sample management, testing analysis, and data management [1] - This collaboration signifies a significant advancement in the company's intelligent autonomous laboratory solutions within the chemical automation sector, validating its technical strength and commercial delivery capabilities [1][2] - The company's modular standard platform and agile customization capabilities have been successfully implemented in high-value fields such as new drug development and chemical synthesis, ensuring efficient deployment and stable operation [2] Group 2 - The automated laboratory solutions have been adopted by various large enterprises and top research institutions, including international pharmaceutical companies and major universities, expanding the company's business boundaries from pharmaceutical research to large-scale chemical and new energy markets [3] - The company aims to deepen strategic collaboration with global industry leaders, accelerating the technological iteration of intelligent laboratories and providing core infrastructure for innovation in industrial research efficiency [3] - The integration of AI in research is positioning the company's automated laboratories as essential infrastructure for future AI-driven research, establishing a unique competitive barrier in the market [2]

本自願公告乃由晶泰控股有限公司（「本公司」，連 同 其 附 屬 公 司 統 稱「本集團」） 作 出，以 知 會 股 東 及 潛 在 投 資 者 有 關 本 集 團 的 最 新 業 務 發 展。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 XtalPi Holdings Limited 晶泰控股有限公司 （於 開 曼 群 島 註 冊 成 立 之 有 限 公 司） （股 份 代 號：2228） 自願性公告 晶 泰 科 技 機 器 人 實 驗 室 落 地 巴 斯 夫， 全球技術領導力獲化工業頂級背書 本公司董事會（「董事會」）欣 然 宣 布，近 日，本 集 團 已 成 功 向 全 球 化 工 巨 頭 巴 斯 夫(BASF)交 付 了 一 種 配 方 穩 定 性 測 試 自 動 化 工 作 站，助 力 巴 斯 夫 構 建 起「樣 品 管 理－測 試 分 析－數 據 管 理」全 鏈 路 的 自 動 化 ...

Group 1 - The company, CaiXun Co., Ltd. (300634.SZ), has announced a plan to issue convertible bonds to unspecified investors, with a total fundraising amount not exceeding RMB 1.46 billion (including principal) [1] - The net proceeds from the bond issuance, after deducting issuance costs, will be invested in several projects, including the construction of a smart computing center, the R&D upgrade of the Rich AIBox platform, and the development of enterprise-level AI intelligent applications [1]

Core Insights - The innovative drug sector is experiencing a significant bull market, with the entry threshold for top-performing stocks raised considerably [1] - In 2024, the median stock price increase for the top 10 innovative drug companies was 57.9%, while in 2025, this surged to a median increase of 495.41%, with the highest increase reaching 1824% [2] Group 1: Top Performing Companies - The top-performing stock in 2025 was Beihai Kangcheng, with an astonishing annual increase of 1824%, surprising many in the market [4] - Following Beihai Kangcheng, the second highest was Sanleaf Biotech, which saw an increase of 870%, despite facing significant operational challenges [10] - Yaojie Ankang ranked third with a 773% increase, although its valuation raised concerns due to its limited clinical progress [12] - Heber Pharmaceuticals achieved a 553% increase, driven by its dual-engine model of R&D and business development [16] - Xuan Bamboo Biotech, a newly listed company, experienced a 507% increase, attributed to its new stock status and positive clinical data [20] Group 2: Market Dynamics and Trends - The market has seen a trend of speculative trading, with some companies experiencing price surges not necessarily backed by fundamental improvements [4] - The rise of companies like Heber Pharmaceuticals and Rongchang Biotech illustrates that long-term undervalued firms can achieve significant valuation recovery through continuous R&D and commercialization breakthroughs [4][30] - The innovative drug sector's growth is heavily influenced by liquidity and market sentiment, with many price increases based on speculative expectations rather than solid fundamentals [39] Group 3: Company-Specific Developments - Beihai Kangcheng's stock price recovery was linked to strategic capital injections, resolving its cash flow crisis [7] - Sanleaf Biotech's stock price rebound was primarily driven by its RSV vaccine pipeline, despite facing significant financial pressures [10][11] - Yaojie Ankang's rapid valuation increase raised questions about its sustainability, given its limited clinical advancements [13][14] - Heber Pharmaceuticals' growth was supported by strategic partnerships and a robust technology platform, enhancing investor confidence [18][19] - Rongchang Biotech's stock performance was bolstered by successful product approvals and strategic financing, improving its market outlook [31]

Core Insights - The article highlights the journey and achievements of Cai Tong, the founder of Yabao Chemical, emphasizing his unique interdisciplinary background and strategic vision in the fine chemical industry [2][3]. Company Development - Yabao Chemical has focused on deepening its core business layout, particularly in the pharmaceutical sector, by signing a strategic cooperation agreement with leading domestic pharmaceutical company Heng Rui Medicine to enhance the quality and efficiency of its pharmaceutical business [3]. - The company has established its Malta base as a bridge for international business, equipped with EU GMP certification and formulation repackaging capabilities, facilitating domestic pharmaceutical companies' expansion into overseas markets [3]. - In the agrochemical intermediate sector, Yabao Chemical is concentrating on innovative, green, and efficient CDMO services, maintaining strategic partnerships with international agrochemical firms such as Corteva, Bayer, and FMC to solidify its leading position in niche markets [3]. Innovation and Investment - During the 14th Five-Year Plan period, Yabao Chemical has invested nearly 600 million yuan in research and development, prioritizing technological innovation as a core growth engine and establishing an AI research laboratory to build an intelligent R&D system [3]. - The company aims to create a diversified business structure encompassing pharmaceuticals, agrochemicals, and other sectors, referred to as "Pharmaceuticals + Agrochemicals + X" [3]. Recognition and Contributions - Cai Tong has received various accolades for his contributions to the industry and society, including the 2010 Taicang City First Lou Dong Talent Award and the 2013 Outstanding Person in China's Service Outsourcing Award [4]. - He holds multiple positions in educational and industry associations, contributing to talent cultivation and regional industrial collaboration [4].

Core Insights - The company, Yabao Chemical, was founded by Cai Tong, who leveraged his interdisciplinary knowledge in chemistry and economics to establish a unique position in the fine chemical industry [2][3] - Yabao Chemical has focused on the CDMO (Contract Development and Manufacturing Organization) segment in fine chemicals, particularly in innovative pharmaceuticals and agrochemicals, leading to its successful listing on the capital market [2][3] Business Development - Yabao Chemical has deepened its core business layout, particularly in the pharmaceutical sector, by signing a strategic cooperation agreement with leading domestic pharmaceutical company, Hengrui Medicine, to enhance the quality and efficiency of its pharmaceutical business [3] - The company’s Malta base serves as a bridge for international business, equipped with EU GMP certification and formulation repackaging capabilities, facilitating domestic pharmaceutical companies' expansion into overseas markets [3] - In the agrochemical intermediate sector, Yabao Chemical focuses on green, efficient, and low-toxicity innovative agrochemical CDMO business, maintaining strategic partnerships with international agricultural companies such as Corteva, Bayer, and FMC [3] Innovation and Investment - During the 14th Five-Year Plan period, Yabao Chemical has invested nearly 600 million yuan in research and development, positioning technology innovation as its core development engine [3] - The company has established an AI research and development laboratory to build an intelligent R&D system, solidifying its technological advantages in the industry [3] Recognition and Contributions - Cai Tong has received various accolades for his contributions to the industry and society, including the 2010 Taicang City First Lou Dong Talent Award and the 2013 Outstanding Person in China's Service Outsourcing Award [4] - He holds multiple positions, including a board member at Fudan University and vice president of the Fudan University Chemistry Alumni Association, contributing to talent cultivation and regional industrial collaboration [4]